And the National Comprehensive Cancer Network (NCCN) recommended pembrolizumab for second-line therapy for esophageal squamous cell carcinoma with PD-L1 CPS ≥ 10 (8). Here, CD274 is linked to esophageal squamous cell carcinoma.